3.2. Clinical aspects of statin users
CVD
Most statin users in this study were prescribed rosuvastatin (50% of participants) or atorvastatin (35.5%). This distribution was expected given the usual clinical practice at the CHU de Québec–Université Laval lipid clinic. A detailed breakdown of the clinical profile of participants in this study is presented in The Framingham Score revealed that the CV risk over ten years was low (<10%) for all patients (except for 1 patient [13%, moderate risk]). Nevertheless, the CV risk for the SAMS group was higher than that of the No SAMS and Control groups (mean +1.43% and +1.96%, respectively.) Most participants in the SAMS and No SAMS groups had been using statins for 12 to 48 months (80.4% and 100% respectively). Nineteen participants indicated having previously not tolerated some forms of statins, their distribution being roughly equal in SAMS and No SAMS groups (respectively 31.9% and 26.7% of participants). Among the 38 participants with a family history (first degree) of CVD, 35 were present in groups treated with statins. 91.3% of participants with a family history (first degree) in terms of lipid-lowering treatment were present in these same statin-taking groups. Finally, of the 30 participants in the SAMS group who reported a family history (first degree) of lipid-lowering therapy, 6 also reported a self-reported family history of SAMS.